Company intelligence / Profile preview

MetaImmuneTech

Sejong, Sejong, South Koreapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

MetaImmuneTech has developed the Cellytics platform, the world’s first single-cell analyzer using digital in-line holography to monitor individual immunity. Their lead product, Cellytics NK, is an innovative point-of-care tool for rapid assessment of natural killer cell activity. The company is preparing to commercialize this as an in vitro diagnostic and plans to expand into additional immune functional assays and home test kits for personalized immune monitoring.

Therapeutic areas: Immunology
Modalities: DeviceDiagnostic platform (immune functional assay system)In vitro diagnostic product
Industry: Physiological Monitoring

Beyond the preview

Go deeper on MetaImmuneTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MetaImmuneTech.

Explore the full profile